- About Us
- Studies for Risk Management
- Consulting on Risk Management
- Other Research Services
- Public Health
- Study Recruitment
The Drug Safety Research Unit (DSRU) is an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training for over 30 years.
In partnership with doctors in England, the DSRU, led by Director Professor Saad Shakir, aims to protect patients in primary and specialist care from unwanted adverse effects of newly marketed medicines using our unique methods of monitoring patients during the lifecycle of medicines.
The Rivaroxaban Observational Safety Evaluation (ROSE) study has received a high level of interest across England and Wales with 78 NHS Trusts currently recruiting. As a result of the success of the study, the target for the non-valvular atrial fibrillation cohort has been reached earlier than expected. The study continues to recruit patients for the other cohorts: deep vein thrombosis and pulmonary embolism.
For a more in-depth update on the ROSE study, please see the latest study newsletter.
ROSE is an example of a SCEM study, which uses the DSRU's novel methodology to monitor the safety of a drug prescribed in secondary care. Further information about SCEM methodology is available here.View our latest news